Exendin-4

Exendin-4 is a protein of the GLP-1 family currently used to treat diabetes. Recently, a greater number of biological properties have been associated with the GLP-1 family. Our data shows that exendin-4 treatment significantly increases the cytoskeleton rearrangement, which leads to an increasingly differentiated phenotype and reduced cell migration. We also found that exendin-4 could prevent SH-SY5Y and PC12 cells from Nogo-A-Δ20 mediated spreading inhibition and neurite collapse. Western blot analysis indicated that exendin-4 treatment both reduced the expression and activation of RhoA via the PI3K signaling pathway. These data suggest that exendin-4 may protect nerve regeneration by preventing the inhibition of Nogo-A via down-regulating RhoA expression and activation 1)


1)
Zhao F, Li J, Wang R, Xu H, Ma K, Kong X, Sun Z, Niu X, Jiang J, Liu B, Li B, Duan F, Chen X. Exendin-4 promotes actin cytoskeleton rearrangement and protects cells from Nogo-A-Δ20 mediated spreading inhibition and growth cone collapse by down-regulating RhoA expression and activation via the PI3K pathway. Biomed Pharmacother. 2018 Nov 2;109:135-143. doi: 10.1016/j.biopha.2018.10.008. [Epub ahead of print] PubMed PMID: 30396070.
  • exendin-4.txt
  • Last modified: 2025/05/13 02:19
  • by 127.0.0.1